Welcome to our dedicated page for Cbdmd news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on Cbdmd stock.
cbdMD, Inc. (NYSE American: YCBD) generates a steady flow of corporate, financial, and strategic news tied to its position in the hemp-derived wellness and cannabinoid products space. Company press releases and SEC filings highlight developments across its cbdMD and Paw CBD brands, ATRx Labs functional mushroom products, and Herbal Oasis hemp-derived THC social seltzers, as well as capital markets activity and exchange-listing matters.
News for YCBD often covers operating performance, including updates on net sales, gross profit, and operating loss trends disclosed in conjunction with annual and quarterly results. The company has reported multiple years of operating improvement and has discussed cost management, product portfolio optimization, and marketing investments in its communications. Investors following YCBD news also see disclosures about preferred stock financings, such as Series B and Series C Convertible Preferred Stock, and the establishment of an equity line of credit registered on Form S-1.
Regulatory and listing-related announcements form another key part of cbdMD’s news flow. The company has reported regaining full compliance with NYSE American continued listing standards after addressing equity-related deficiencies, and it has furnished related information through Form 8-K filings. Policy commentary around federal discussions on cannabinoids and hemp-derived products, and how those discussions may affect research and investment in the category, also appears in its releases.
Strategic updates, including the asset acquisition of Gaia Botanicals, LLC and its Bluebird Botanicals brand and online CBD marketplace, are disclosed through press releases and 8-K filings. These items provide detail on how cbdMD is expanding its brand portfolio, intellectual property base, and product offerings in CBD and related categories. For investors and observers, the YCBD news page offers a centralized view of earnings communications, capital transactions, regulatory milestones, and brand-level initiatives across cbdMD’s wellness platform.
cbdMD (NYSE American: YCBD) will host a conference call on Friday, December 19, 2025 at 4:20 p.m. ET to discuss its September 30, 2025 fourth quarter and fiscal year 2025 financial results and business progress.
Investors in the USA/Canada can join by phone at 888-880-3330. A live webcast and replay are available via the provided link and will remain accessible through December 19, 2026.
cbdMD (NYSE American: YCBD) announced it has regained full compliance with NYSE American listing standards and that the “.BC” noncompliance indicator was removed effective at the open of trading on December 8, 2025. The NYSE American notified the company on December 5, 2025 that cbdMD resolved deficiencies under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.
Management highlighted the May Series A Preferred share conversion and a capital raise completed in September as key elements of the company’s compliance plan. cbdMD said it will remain subject to NYSE American continued listing monitoring procedures and will file a Form 8-K with the SEC on December 8, 2025 for additional details.
cbdMD (NYSE American: YCBD) announced it has regained full compliance with NYSE American listing standards and that the “.BC” noncompliance indicator was removed effective at the open of trading on December 8, 2025. The NYSE American notified the company on December 5, 2025 that cbdMD resolved deficiencies under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.
Management highlighted the May Series A Preferred share conversion and a capital raise completed in September as key elements of the company’s compliance plan. cbdMD said it will remain subject to NYSE American continued listing monitoring procedures and will file a Form 8-K with the SEC on December 8, 2025 for additional details.
cbdMD (NYSE American: YCBD) reported preliminary unaudited results for the fourth quarter and fiscal year ended September 30, 2025. Fiscal 2025 net sales are expected to be between $19.1M and $19.3M versus $19.5M in fiscal 2024, and Q4 net sales are expected to be $4.7M–$4.9M vs $4.6M in Q4 2024 (a 3%–5% increase).
Fiscal 2025 net loss is expected to improve to $1.9M–$2.1M from a $3.7M loss in 2024. Management attributes improvement to cost discipline and operating changes and plans a mid-December earnings call to discuss results.
cbdMD (NYSE American: YCBD) reported preliminary unaudited results for the fourth quarter and fiscal year ended September 30, 2025. Fiscal 2025 net sales are expected to be between $19.1M and $19.3M versus $19.5M in fiscal 2024, and Q4 net sales are expected to be $4.7M–$4.9M vs $4.6M in Q4 2024 (a 3%–5% increase).
Fiscal 2025 net loss is expected to improve to $1.9M–$2.1M from a $3.7M loss in 2024. Management attributes improvement to cost discipline and operating changes and plans a mid-December earnings call to discuss results.
cbdMD (NYSE American: YCBD) expanded its Herbal Oasis hemp-derived THC-infused social seltzer lineup on October 22, 2025 with two new 10mg flavors: Berry Fusion 10mg and Tropic Wave 10mg. Each 12oz slim can contains 10mg hemp-derived THC and is infused with CBG plus functional mushrooms (lion's mane, reishi, cordyceps).
The launch follows consumer testing (small batch pilots, tastings, surveys, social listening) and targets Sober October demand for alcohol alternatives. Products are available now at herbaloasis.com and rolling out to select retail partners. The release cites market data forecasting U.S. THC beverage sales at $1.1B in 2024 and >25% growth in 2025.
cbdMD (NYSE American: YCBD) announced that its Herbal Oasis THC-infused social seltzer is expanding distribution across most of Florida via a new partnership with Bevtalk Distribution.
Bevtalk will target convenience stores, independent retailers, and specialty beverage accounts, with first shipments already begun and broader placements rolling out through the remainder of 2025. Herbal Oasis blends hemp-derived THC, CBG, and adaptogenic mushrooms and is available in flavors including Lemon Lift, Berry Fusion, Tropical Twist, Mango Bliss, and Tropic Wave. The release cites a growing THC beverage category—estimated $1.1B in U.S. sales in 2024 and projected >25% growth in 2025.
cbdMD (NYSE American: YCBD) announced that its Herbal Oasis THC-infused social seltzer is expanding distribution across most of Florida via a new partnership with Bevtalk Distribution.
Bevtalk will target convenience stores, independent retailers, and specialty beverage accounts, with first shipments already begun and broader placements rolling out through the remainder of 2025. Herbal Oasis blends hemp-derived THC, CBG, and adaptogenic mushrooms and is available in flavors including Lemon Lift, Berry Fusion, Tropical Twist, Mango Bliss, and Tropic Wave. The release cites a growing THC beverage category—estimated $1.1B in U.S. sales in 2024 and projected >25% growth in 2025.
cbdMD (NYSE American: YCBD) has secured a $1.7 million private placement through the issuance of Series B Convertible Preferred Stock to institutional investors, including C/M Capital Master Fund, LP. The company will receive net proceeds of $1.5 million for working capital and strategic initiatives.
The preferred shares feature a 10% annual dividend and are convertible to common stock at $1.00 per share. CEO Ronan Kennedy highlighted that the company will end its fiscal year with over $2.2 million in cash, strengthening their balance sheet and supporting efforts to regain full listing compliance while expanding distribution of their consumer brands.
cbdMD (NYSE American: YCBD) has launched Inferno Freeze, its most powerful topical product designed for athletes and fitness enthusiasts. The new product features an advanced full-spectrum formula containing 3000mg CBD, 500mg CBDa, and 50mg THC combined with cooling agents including 4% Menthol, 3% Camphor, and 0.04% Capsaicin.
The product utilizes nano-technology for enhanced absorption and effectiveness, incorporating USA-grown hemp and non-GMO ingredients. This launch expands cbdMD's topicals line and complements their existing portfolio of ingestibles, pet products, functional mushrooms, and hemp-derived beverages.